Thyroid Cancer in Kazakhstan: Component Analysis of Incidence Dynamics.
Component analysis
Incidence
Kazakhstan
Thyroid cancer
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 09 2019
01 09 2019
Historique:
received:
21
05
2019
entrez:
27
9
2019
pubmed:
27
9
2019
medline:
15
2
2020
Statut:
epublish
Résumé
Background: The International Agency for Research on Cancer (IARC) reports that 567,000 new cases of thyroid
cancer (TC) were registered in the world in 2018, and the age-standardized incidence rate was 6.7 per 100,000. The
Global Cancer Observation forecasts a 35% growth in the number of new cases worldwide by 2040. The number of
patients with TC in Kazakhstan is also increasing steadily. This investigation was the first epidemiological study of TC
trends by component analysis among the population of Kazakhstan. This paper presents the results of the component
analysis of TC incidence trends in Kazakhstan. Methods: The study covers primary data of TC cases (ICD 10 – C73)
registered throughout Kazakhstan from 2009 to 2018. TC incidence trends were evaluated using component analysis
according to the methodological recommendations. Results: 5,559 new TC cases were registered during the 10-year
study period. The average age of patients was 52.0±0.2 years, the average annual age-standardized rate in 2009-2018
was 3.3±0.20/0000, with a constant upward trend (Т=+6.6%). According to the component analysis results, the increase
in incidence was mainly due to the combined effect of the two factors: the increased disease risk (ΔR=+61.7%), and
the population growth (ΔP=+15.4%). Conclusion: The noted increase in incidence was mainly caused by the changes
in risk factors, such as the worsening environmental aspects and the increase in detection of clinically non-manifesting
cases. The results of the study shall be taken into account when planning anticancer activities for TC.
Identifiants
pubmed: 31554390
doi: 10.31557/APJCP.2019.20.9.2875
pmc: PMC6976859
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2875-2880Références
Curr Opin Endocrinol Diabetes Obes. 2017 Oct;24(5):332-336
pubmed: 28692457
Int J Cancer. 2013 Mar 1;132(5):1222-6
pubmed: 22847218
Cancer Res Treat. 2012 Mar;44(1):11-24
pubmed: 22500156
Thyroid. 2018 Jan;28(1):11-22
pubmed: 28954584
Iran J Public Health. 2016 Aug;45(8):1012-1019
pubmed: 27928527
Nat Rev Cancer. 2006 Jan;6(1):63-74
pubmed: 16372017
Cancer. 2015 Feb 1;121(3):457-66
pubmed: 25351557
Asian Pac J Cancer Prev. 2013;14(3):1945-9
pubmed: 23679297
Nature. 1992 Sep 3;359(6390):21
pubmed: 1522879
Asian Pac J Cancer Prev. 2016;17(1):377-80
pubmed: 26838242
Radiat Res. 2016 May;185(5):473-84
pubmed: 27128740
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
Asian Pac J Cancer Prev. 2015;16(6):2289-93
pubmed: 25824752
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2207-2217
pubmed: 28368520
BMJ. 2016 Nov 30;355:i5745
pubmed: 27903497